Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. reported significant growth in net product revenues and improvements in net loss for the fiscal year 2025, driven by increased sales and strategic partnerships [5][4]. Financial Highlights - FY 2025 net product revenues increased by 65% to $1.005 million, up from $607.6 thousand in 2024, attributed to rising sales, price increases, and fewer returns [5]. - Gross profit for 2025 was approximately $223.8 thousand, slightly up from $222.8 thousand in 2024, despite inventory write-offs related to short-dated products [5]. - Operating expenses decreased to approximately $8.4 million in 2025 from $10.0 million in 2024, with a notable reduction in R&D costs [5]. - Net loss attributable to common shareholders improved to approximately $7.37 million, or $11.73 per share, compared to a net loss of approximately $7.96 million, or $74.17 per share, in 2024 [5]. Recent Business Highlights - In March 2026, the company announced successful outcomes in its expanded access study for relapsing babesiosis, leading to calls for revised treatment guidelines [5]. - A partnership with GoodRx was established in February 2026 to offer savings on ARAKODA®, expanding its sales footprint to over 70,000 pharmacies [5]. - The company exercised its Florida State University license option for large-scale purification of castanospermine in January 2026, indicating readiness to begin regulatory processes for Australian Chestnut Extract [5]. - A Phase 2 B-FREE Chronic Babesiosis Study commenced in November 2025, aiming to enroll up to 100 patients [5]. - A sponsored research agreement with Tulane University was signed in July 2025 to evaluate tafenoquine's activity against Lyme and Bartonella bacteria [5].

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. has submitted a New Dietary Ingredient Notification for Australian Chestnut Extract to the FDA, with a marketing opportunity expected post-May 25, 2026, if no objections arise [1][9] Group 1: Company Developments - The company has signed an option agreement with Florida State University (FSU) to license rights related to new capsule formulation methods for Australian Chestnut Extract, building on a previous license for large-scale purification of Castanospermine [2][9] - 60 Degrees Pharmaceuticals specializes in developing medicines for vector-borne diseases and received FDA approval for its lead product, ARAKODA® (tafenoquine), in 2018, which is available in the U.S. and Australia [6] Group 2: Product Information - Australian Chestnut Extract is derived from the seeds of Castanospermum australe, with castanospermine as its dominant molecular constituent [3] - Scientific literature indicates that castanospermine can modulate carbohydrate metabolism at low doses and has shown potential in impacting disease outcomes through immunomodulation in animal models [4] - Castanospermine is a metabolite of celgosivir, previously evaluated in clinical trials for HIV and Hepatitis C, suggesting its safety and efficacy at achievable doses in humans [5]

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. is initiating the regulatory process to gain access to the U.S. market for Australian Chestnut Extract as a botanical product for non-prescription uses [1][5]. Group 1: Company Developments - The company has exercised its option with Florida State University to negotiate an exclusive license for large-scale purification techniques to extract castanospermine from Australian Chestnut seeds [1]. - Since signing the option agreement in April 2025, the company has conducted safety testing on Australian Chestnut Extract and developed various prototype capsule formulations for oral delivery [5]. - 60 Degrees Pharmaceuticals specializes in developing new medicines for vector-borne diseases and received FDA approval for its lead product, ARAKODA, in 2018 [6]. Group 2: Product Information - Castanospermum australe, the source of castanospermine, is primarily found in Queensland and New South Wales, Australia, as well as in Florida, Hawaii, and California [2]. - Castanospermine has been shown to modulate carbohydrate metabolism and impact disease outcomes in animal models through immunomodulation [3]. - It is also a metabolite of celgosivir, which has been evaluated in clinical trials against HIV and Hepatitis C, suggesting castanospermine's safety and activity against similar pharmacological targets [4].